A holistic approach that treats the stack as a coupled physical system helps overcome thermal, stress, and reliability ...
A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...
Shares in Ironwood Pharma fell by a third after it revealed that the FDA is insisting on a new phase 3 trial of its short bowel syndrome therapy before it can consider approval. The outcome of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback